(BUSINESS WIRE)-- Quintiles has received the prestigious 2013 Informatica Innovation Award for “Enterprise Data Integration” recognizing its pioneering efforts, through the Quintiles Infosario® solution, to integrate and master both clinical research and healthcare data across numerous institutions and at a scale never before accomplished in the biopharmaceutical industry.
Quintiles Infosario seamlessly integrates data, systems, processes and Quintiles’ therapeutic expertise to unlock faster, better-informed decisions from clinical trial planning and design to trial execution services, through post-market outcome studies. It uniquely allows for scientific and operational design to inform and optimize operations based on real-time alerts and data insights, mitigating risk, while improving patient safety, productivity and time to market.
The Informatica Innovation Awards honor organizations that have demonstrated leadership through the application of Informatica technologies that yielded significant business results. Out of more than 5,000 eligible companies and organizations, winners in 12 categories were announced at the annual Informatica user conference, Informatica World 2013.
“We are honored to have Quintiles Infosario recognized as one of the world’s leading data integration solutions,” said Quintiles Chief Information Officer Richard Thomas.
“At the core of Quintiles Infosario is our data factory which integrates a wide variety of clinical, healthcare and operational data across a significant number of sources ranging from pharmaceutical companies to hospital and care provider networks. Being able to combine this data and add context / meaning results in highly actionable analytics which our customers really appreciate,” Thomas concluded.
About Quintiles
Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes.
Click here to subscribe to Mobile Alerts for Quintiles.
Contacts
Quintiles
Media Relations:
Phil Bridges, + 1-919-998-1653
Mobile: +1-919-259-3298
phil.bridges@quintiles.com
or
Investor Relations:
Karl Deonanan, +1-919-998-2789
InvestorRelations@quintiles.com
Permalink: http://www.me-newswire.net/news/7612/en
No comments:
Post a Comment